Intas Pharmaceuticals sells ChrysCapital’s stake to Temasek

NEW DELHI: Intas Pharmaceuticals Ltd, one of India’s fastest growing pharmaceutical companies, has announced that Singapore investment company Temasek has acquired a 10.16% equity stake in the company by way of secondary purchase of shares from private equity investor ChrysCapital.

Intas is a leading, vertically-integrated global pharmaceutical company from India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. With three decades of progressive strategies, productive R&D, biotechnological expertise and investments in ten advanced manufacturing facilities across the globe, Intas has emerged as one of the fastest-growing pharmaceutical organizations in the world.

Binish Chudgar, vice chairman and managing director of Intas Pharmaceuticals, said, “Intas is the 12th largest player in the Indian pharmaceuticals market with a strong chronic oriented portfolio. It is ranked 4th largest in chronic therapy areas with a strong presence in cardiac-diabeto and neuropsychiatry therapeutic segments. Over the past few years, Intas has successfully transitioned into a global generics player with over 50% of its revenues now coming from international markets. It has a global presence in over 70 countries, backed by a strong product basket, pipeline and marketing infrastructure. Presently the US & Europe account for almost 75% of total international revenues and both these geographies continue to exhibit strong growth.”

The company is investing significant resources to build a pipeline of novel drug delivery technology-based products. Intas has become the first company in the world to launch a Nanosomal Docetaxel Lipid Suspension (NDLS), DoceAqualip, designed to significantly reduce the hypersensitivity of the drug among the patients.

Binish further stated that “ChrysCapital has been a valuable partner for Intas over the years. We are delighted to have lived up to the expectation of ChrysCapital and now look forward to welcoming a globally reputed investor like Temasek to enable Intas to reach greater heights in the years to come.”

Temasek’s investment deepens its exposure to India’s pharmaceuticals industry through a company with deepening comparative advantages. The sector is a good proxy for the needs of transforming economies, which is part of Temasek’s investment themes.